Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets
Cumulus Oncology and leadXpro Announce Collaboration.
Resulting IP will be licensed into a newly created Cumulus company
Latest developments, partnerships and scientific breakthroughs
Cumulus Oncology and leadXpro Announce Collaboration.
Resulting IP will be licensed into a newly created Cumulus company
Early drug discovery requires an interdisciplinary approach with a sophisticated interplay between empirical methods and rational design. Amongst the different therapeutic modalities, orally available small molecules are a major pillar for safe treatment of acute and chronic diseases.
In this collaboration, leadXpro will establish robust protocols and workflows to facilitate the rapid determination
During this engagement, leadXpro will use membrane proteins selected by Septerna to discover novel binding partners to…
We are thrilled to announce that leadXpro has extended its cryo-EM facility with the latest technology in sample preparation solution, the VitroJet. This cutting-edge technology is the first of its kind in Switzerland.
To date, no structural information has been reported for the entire H+ activated GPCR family.
In collaboration with Merck/Serono, leadXpro confirmed the colocalization aspect of the mode of action of bintrafusp alfa using Cryo-Electron Microscopy
leadXpro AG is a sponsor of the MabDesign Network, which aims at structuration of the immunotherapeutics research sector.
Listen to Michael Hennig’s talk at DDC 2022 about the impact of CGI and other biophysical methods on drug discovery for membrane proteins
The PSDI conference 2021 will take place online. leadXpro scientist Mathieu Botte will present on Cryo-EM applications.